Abstract
Recent discoveries in epidemiology and molecular epidemiology suggest a link between cancer risk, cancer progression and diabetes risk factors and treatment. Obesity, physical inactivity, smoking, mal nutrition and age are common risk nominators for both diseases. Furthermore due to these risk factors, tumor patients are often comorbid with diabetes type 2. Therefore, it is an urgent need in order to meet at least one risk factor - obesity and mal nutrition - to show that - in a scientifically well-based manner - ethnopharmacology can provide views on plants with health informations. Apart from epidemiological evidence, selected botanicals have to be proven in preclinical and cellular settings, in animal studies for the proof of principle and in clinical trials for their potentials as dietary nutritional care. We have shown here for the first time according to this scientific sequencing of evaluation that a special water soluble Bitter Melon powder is a first candidate to be included into personalized diabetes type 2 and antitumor protocols as dietary supportive care to control the carbohydrate metabolism. The proof of principle to decrease blood glucose values in db/db mice by a Bitter Melon powder was demonstrated and a prospective, randomized, double-blinded and Placebo-controlled trial in diabetes type 2 patients, although continuously throughout the trial under conventional oral therapy, gave evidence for a Bitter Melon powder to be able to decrease HbA1c in a four-months intervention. This study highlights the importance of a significantly evaluated botanical as supportive diet care in tumor and diabetes type 2 patients.
Keywords: Diabetes Type 2, cancer, bitter melon, Momordica charantia L, human clinical study, prospective and doubleblinded, dietary supportive care, personalized medicine
Current Cancer Therapy Reviews
Title: Personalized Diabetes and Cancer Medicine: A Rationale for Anti-Diabetic Nutrition (Bitter Melon) in a Supportive Setting
Volume: 8 Issue: 1
Author(s): Zanker K.S., Mang B., Wolters M and Hahn A.
Affiliation:
Keywords: Diabetes Type 2, cancer, bitter melon, Momordica charantia L, human clinical study, prospective and doubleblinded, dietary supportive care, personalized medicine
Abstract: Recent discoveries in epidemiology and molecular epidemiology suggest a link between cancer risk, cancer progression and diabetes risk factors and treatment. Obesity, physical inactivity, smoking, mal nutrition and age are common risk nominators for both diseases. Furthermore due to these risk factors, tumor patients are often comorbid with diabetes type 2. Therefore, it is an urgent need in order to meet at least one risk factor - obesity and mal nutrition - to show that - in a scientifically well-based manner - ethnopharmacology can provide views on plants with health informations. Apart from epidemiological evidence, selected botanicals have to be proven in preclinical and cellular settings, in animal studies for the proof of principle and in clinical trials for their potentials as dietary nutritional care. We have shown here for the first time according to this scientific sequencing of evaluation that a special water soluble Bitter Melon powder is a first candidate to be included into personalized diabetes type 2 and antitumor protocols as dietary supportive care to control the carbohydrate metabolism. The proof of principle to decrease blood glucose values in db/db mice by a Bitter Melon powder was demonstrated and a prospective, randomized, double-blinded and Placebo-controlled trial in diabetes type 2 patients, although continuously throughout the trial under conventional oral therapy, gave evidence for a Bitter Melon powder to be able to decrease HbA1c in a four-months intervention. This study highlights the importance of a significantly evaluated botanical as supportive diet care in tumor and diabetes type 2 patients.
Export Options
About this article
Cite this article as:
K.S. Zanker, B. Mang, M Wolters and A. Hahn, Personalized Diabetes and Cancer Medicine: A Rationale for Anti-Diabetic Nutrition (Bitter Melon) in a Supportive Setting, Current Cancer Therapy Reviews 2012; 8 (1) . https://dx.doi.org/10.2174/157339412799462521
DOI https://dx.doi.org/10.2174/157339412799462521 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics
The thematic issue "Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics" aims to explore the cutting-edge developments and innovative strategies in the field of lipid nanoparticle (LNP) technology, particularly focusing on its application in mRNA delivery. This topic has gained unprecedented attention and urgency in the wake of the ...read more
Current progress in Protein Degradation and Cancer Therapy
Targeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Immunomodulation Mechanism of Antidepressants: Interactions between Serotonin/Norepinephrine Balance and Th1/Th2 Balance
Current Neuropharmacology Carcinogenicity and Chronic Rodent Toxicity of the Selective Progesterone Receptor Modulator Ulipristal Acetate
Current Drug Safety PI3K Pathway Inhibitors: Better Not Left Alone
Current Pharmaceutical Design Adrenocortical Crisis Triggered by Levothyroxine in an Unrecognized Autoimmune Polyglandular Syndrome Type-2: A Case Report with Review of the Literature
Current Drug Safety Beyond the Reproductive Effect of Sex Steroids: Their Role During Immunity to Helminth Parasite Infections
Mini-Reviews in Medicinal Chemistry Management of Postoperative Nausea and Vomiting in Women Undergoing Major Gynecological Surgery: A Review and Update
Current Drug Therapy Retraction Notice: Current Management of Vomiting After Tonsillectomy in Children
Current Drug Safety A Timely Review of State-of-the-Art Chronopharmaceuticals Synchronized with Biological Rhythms
Current Drug Delivery Strategies for the Assessment of Metabolic Profiles of Steroid Hormones in View of Diagnostics and Drug Monitoring: Analytical Problems and Challenges
Current Drug Metabolism The Potential Use of Hormone-Based Therapeutics for the Treatment of Alzheimers Disease
Current Alzheimer Research Chloro-s-triazines-toxicokinetic, Toxicodynamic, Human Exposure, and Regulatory Considerations
Current Drug Metabolism CYP17 Inhibitors for Prostate Cancer Treatment – An Update
Current Medicinal Chemistry Targeting Receptor Tyrosine Kinases Using Monoclonal Antibodies: The Most Specific Tools for Targeted-Based Cancer Therapy
Current Drug Targets Phase I Clinical Trial of Exherin (ADH-1) in Patients with Advanced Solid Tumors
Current Clinical Pharmacology Formulation and Application of Biodegradable Nanoparticles Based Biopharmaceutical Delivery - An Efficient Delivery System
Current Pharmaceutical Design Interactions of the Aryl Hydrocarbon Receptor with Inflammatory Mediators:Beyond CYP1A Regulation
Current Drug Metabolism Molecular Methods for Individualization of Psychotropic Drug Treatment
Current Pharmacogenomics Type 2 Diabetes and Risk for Functional Decline and Disability in Older Persons
Current Diabetes Reviews Cytokine-Induced Depression: Current Status and Novel Targets for Depression Therapy
CNS & Neurological Disorders - Drug Targets Mechanisms of Melatonin in Alleviating Alzheimer’s Disease
Current Neuropharmacology